Description
BSE announces the upcoming listing of equity shares of Gaudium IVF and Women Health Limited (scrip code 544709, symbol GAUDIUMIVF) on the Exchange. The exact listing date will be communicated via a separate notice.
Summary
BSE has issued Notice No. 20260226-7 informing trading members that the equity shares of Gaudium IVF and Women Health Limited will be listed and admitted to dealings on BSE. The exact date of listing will be communicated through a separate notice.
Key Points
- Gaudium IVF and Women Health Limited is being listed on BSE under the Equity segment.
- Scrip Code: 544709
- Trading Symbol: GAUDIUMIVF
- ISIN: INE0P8B01020
- The listing date and full security details will be announced in a subsequent notice.
Regulatory Changes
No regulatory changes introduced. This is a standard listing admission notice under BSE’s existing listing framework.
Compliance Requirements
Trading members are advised to take note of the upcoming listing. Further operational details (lot size, price band, etc.) will be provided in the follow-up notice prior to the listing date.
Important Dates
- Notice Date: February 26, 2026
- Listing Date: To be announced via a separate notice.
Impact Assessment
This circular signals the imminent debut of Gaudium IVF and Women Health Limited on BSE. As a healthcare company focused on IVF and women’s health, it may attract interest from investors in the healthcare and fertility sector. The actual market impact will be assessable once the listing date and price details are confirmed in the follow-up notice.
Impact Justification
Standard new equity listing notice for a healthcare company; date of listing is yet to be announced via separate notice, limiting immediate trading impact.